Furthermore, ICIs such as anti-PD1/PD-L1, in combination with PE chemotherapy, have proven efficacy in extensive-stage SCNE lung cancer as front-line therapy and recurrent, persistent, or metastatic cervical cancer. The gene discussed is CD274; the disease is lung cancer.